Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of 64Cu-DOTA-Trastuzumab Positron Emission Tomography in Treatment of Advanced HER2 Positive Breast Cancer With the Antibody Drug Conjugate Ado-trastuzumab Emtansine

NCT02226276 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT02226276
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02226276 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of 64Cu-DOTA-Trastuzumab Positron Emission Tomography in Treatment of Advanced HER2 Positive Breast Cancer With the Antibody Drug Conjugate Ado-trastuzumab Emtansine
Lead sponsor
City of Hope Medical Center
Phase
Not applicable
Overall status
Active, not recruiting
Start date
January 7, 2015
Completion date
September 29, 2026
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases, her2-positive breast cancer, liver metastases, lung metastases, recurrent breast cancer, soft tissue metastases, stage iv breast cancer